Loading…
Oragenics Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in OGEN.
▼ -100.0% over 5Y.
today you would have $0.43▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.78 | $11.10 | $168.90 | $198.00 | $810.00 | $810.00 | $936.00 | $1,548.00 | $4,140.00 | $9,720.00 | $27,000.00 | $16,020.00 | $50,580.00 | $47,520.00 | $18,180.00 | $54,000.00 | |
| P/S |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ONCOOnconetix, Inc. | $0.61 | 0.0x | 0.2x | — | -105.23% | $2.42M |
| CRISCuris Inc | $0.95 | 0.3x | 0.4x | — | — | $2.31M |
| RNAZTranscode Therapeutics, Inc. | $2.18 | — | 1.6x | — | -59.28% | $2.31M |
| VRAXVirax Biolabs Group Ltd | $2.82 |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Company description provided by Yahoo Finance.
| 76.4x |
| — |
| — |
| 670.0x |
| 101.6x |
| 602.1x |
| — |
| — |
| — |
| — |
| — |
| — |
| 34.3x |
| 98.3x |
| 54.5x |
| 8.5x |
| 13.0x |
| P/B | 2.9x | 0.4x | — | 8.0x | 1.0x | 2.0x | 2.9x | 1.4x | 1.9x | 1.8x | 9.0x | 12.7x | 3.1x | 6.4x | 7.9x | — | — |
| EPS | -$4.56 | -$47.88 | -$275.40 | -$213.30 | -$252.00 | -$846.00 | -$666.00 | -$1,566.00 | -$2,466.00 | -$2,826.00 | -$5,760.00 | -$2,880.00 | -$10,080.00 | -$13,320.00 | -$24,120.00 | -$25,560.00 |
| Profit margin | -1269.82% | — | — | -54858.14% | -10863.96% | -18062.03% | — | — | — | — | — | — | -615.95% | -1556.70% | -982.94% | -531.61% | -596.31% |
| ROE | -109.83% | -118.85% | — | -651.98% | -109.83% | -59.32% | -156.91% | -90.33% | -47.48% | -106.57% | -236.48% | -247.54% | -56.01% | -101.45% | -141.80% | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.2x |
| — |
| -78.65% |
| $2.25M |
| IVFINVO Fertility, Inc. | $1.00 | 0.0x | 0.1x | — | -55.28% | $2.51M |
| CMNDClearmind Medicine Inc. | $1.76 | — | 0.2x | — | -114.61% | $2.61M |